Drug intelligence / Profile preview

butalbital + acetaminophen + caffeine

Development stage: Approved
Lead developer: KVK Tech
Modality: Small Molecules
Administration: Oral

Overview

butalbital + acetaminophen + caffeine is a fixed-dose combination product manufactured by KVK-Tech, indicated for the treatment of tension (muscle contraction) headaches. The combination consists of butalbital, a barbiturate that provides sedative and muscle-relaxant effects; acetaminophen, a non-opioid analgesic and antipyretic; and caffeine, a central nervous system stimulant that enhances the analgesic efficacy of the other components. This product is a generic version of the brand-name drug Fioricet. Due to the presence of butalbital, the medication carries a risk of habit-forming potential and abuse.

Other names: butalbital, acetaminophen, and caffeine tablets

Targets

ADOR (Adenosine receptors)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on butalbital + acetaminophen + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on butalbital + acetaminophen + caffeine.

Explore the full profile